Logo image of CLNY

Colony Capital Inc (CLNY) Stock Fundamental Analysis

NYSE:CLNY - New York Stock Exchange, Inc. -

8.5  +0.52 (+6.52%)

After market: 8.18 -0.32 (-3.76%)

Fundamental Rating

1

CLNY gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 128 industry peers in the Diversified REITs industry. CLNY has a bad profitability rating. Also its financial health evaluation is rather negative. CLNY is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

CLNY had negative earnings in the past year.

1.2 Ratios

Industry RankSector Rank
ROA -15.52%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

Industry RankSector Rank
OM -140.48%
PM (TTM) -193.24%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

0

2. Health

2.1 Basic Checks

CLNY has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

A Debt/Equity ratio of 1.08 is on the high side and indicates that CLNY has dependencies on debt financing.
Industry RankSector Rank
Debt/Equity 1.08
Debt/FCF N/A
Altman-Z N/A
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

Industry RankSector Rank
Current Ratio N/A
Quick Ratio N/A

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 37.39% over the past year.
The Revenue for CLNY has decreased by -41.59% in the past year. This is quite bad
CLNY shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 9.25% yearly.
EPS 1Y (TTM)37.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%26.32%
Revenue 1Y (TTM)-41.59%
Revenue growth 3Y-21.43%
Revenue growth 5Y9.25%
Sales Q2Q%-37.79%

3.2 Future

CLNY is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.61% yearly.
The Revenue is expected to grow by 2.23% on average over the next years.
EPS Next Y21.74%
EPS Next 2Y37.1%
EPS Next 3Y23.9%
EPS Next 5Y14.61%
Revenue Next Year-20.16%
Revenue Next 2Y-9.7%
Revenue Next 3Y-1.73%
Revenue Next 5Y2.23%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
CLNY Yearly Revenue VS EstimatesCLNY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B
CLNY Yearly EPS VS EstimatesCLNY Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -2 -4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

CLNY reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CLNY is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CLNY Price Earnings VS Forward Price EarningsCLNY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -14.69
CLNY Per share dataCLNY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

CLNY's earnings are expected to grow with 23.90% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y37.1%
EPS Next 3Y23.9%

More info and screens

1

5. Dividend

5.1 Amount

With a Yearly Dividend Yield of 1.29%, CLNY has a reasonable but not impressive dividend return.
With a Dividend Yield of 1.29, CLNY pays less dividend than the S&P500 average, which is at 2.27.
Industry RankSector Rank
Dividend Yield 1.29%

5.2 History

The dividend of CLNY decreases each year by -22.76%.
CLNY has been paying a dividend for over 5 years, so it has already some track record.
Dividend Growth(5Y)-22.76%
Div Incr YearsN/A
Div Non Decr YearsN/A
CLNY Yearly Dividends per shareCLNY Yearly Dividends per shareYearly Dividends per share 2015 2016 2018 2019 2020 0.5 1 1.5

5.3 Sustainability

The earnings of CLNY are negative and hence is the payout ratio. CLNY will probably not be able to sustain this dividend level.
DP-4.92%
EPS Next 2Y37.1%
EPS Next 3Y23.9%

More info and screens

Colony Capital Inc

NYSE:CLNY (6/21/2021, 8:04:00 PM)

After market: 8.18 -0.32 (-3.76%)

8.5

+0.52 (+6.52%)

Chartmill FA Rating
GICS SectorReal Estate
GICS IndustryGroupEquity Real Estate Investment Trusts (REITs)
GICS IndustryDiversified REITs
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners0%
Inst Owner Change0%
Ins Owners1.22%
Ins Owner Change0%
Market Cap4.14B
Analysts100
Price Target8.61 (1.29%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 1.29%
Yearly Dividend0.11
Dividend Growth(5Y)-22.76%
DP-4.92%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.1
P/FCF N/A
P/OCF N/A
P/B 0.65
P/tB N/A
EV/EBITDA -14.69
EPS(TTM)-1.39
EYN/A
EPS(NY)-0.19
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS2.74
BVpS13.04
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -15.52%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM -140.48%
PM (TTM) -193.24%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.08
Health
Industry RankSector Rank
Debt/Equity 1.08
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio N/A
Quick Ratio N/A
Altman-Z N/A
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)37.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%26.32%
EPS Next Y21.74%
EPS Next 2Y37.1%
EPS Next 3Y23.9%
EPS Next 5Y14.61%
Revenue 1Y (TTM)-41.59%
Revenue growth 3Y-21.43%
Revenue growth 5Y9.25%
Sales Q2Q%-37.79%
Revenue Next Year-20.16%
Revenue Next 2Y-9.7%
Revenue Next 3Y-1.73%
Revenue Next 5Y2.23%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A